-
Product Insights
New![]()
GLS Schleiden Wind Farm_Repowered
GLS Schleiden Wind Farm_Repowered is an Onshore Wind project located in North Rhine-Westphalia, Germany. The project came online in 2015. Empower your strategies with our GLS Schleiden Wind Farm_Repowered report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability...
-
Product Insights
New![]()
DNV GL Kom Ombo Solar PV Park
DNV GL Kom Ombo Solar PV Park is a solar PV project located in Aswan, Egypt. The project is owned and developed by TSK Electronica y Electricidad SA. The project came online in 2020. Empower your strategies with our DNV GL Kom Ombo Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GL-7190 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GL-7190 in Inflammation Drug Details:GL-7190 is under development for the treatment of immunological disorders like inflammation....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GL-0034 in Obesity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GL-0034 in Obesity Drug Details: GL-0034 is under development for the treatment of type...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GLS-6100 in Hepatitis C
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GLS-6100 in Hepatitis C Drug Details: GLS-6100 is under development for the prevention of hepatitis C...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GLS-012 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GLS-012 in Solid Tumor Drug Details: GLS-012 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GL-0034 in Type 2 Diabetes
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GL-0034 in Type 2 Diabetes Drug Details: GL-0034 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zimberelimab in Gastric Cancer Drug Details: Zimberelimab (Sepalizumab) is a human monoclonal monospecific antibody that belongs...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene Nanivacirepvec in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene Nanivacirepvec in Endometrial Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene nanivacirepvec in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene nanivacirepvec in Peritoneal Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.